Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial

Soo Lim, Supawan Buranapin, Xiao-lei Bao, María Florencia Quiroga, Kyung Hee Park, Jee‐Hyun Kang, Anders R. Nielsen, Arisara Suwanagool